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Summary
Objectives:  This  study  was  undertaken  to  investigate  the  clonal  relatedness  of
multidrug-resistant  (MDR)  Acinetobacter  baumannii  isolates  collected  from  patients
in  two  teaching  hospitals  in  Kuwait.
Materials  and  methods:  Clinically  signiﬁcant  consecutive  isolates  of  A.  baumannii
obtained  from  patients  in  the  Mubarak  (36)  and  Adan  (58)  hospitals  over  a  period
of  6  months  were  studied.  These  isolates  were  identiﬁed  using  molecular  methods,
and  their  antimicrobial  susceptibility  was  determined  by  the  Etest  method.  The
mechanism  of  resistance  to  carbapenem  was  investigated  by  PCR,  and  pulsed-ﬁeld
gel  electrophoresis  (PFGE)  was  used  to  determine  the  clonal  relatedness  of  MDR
isolates.
Results:  Of  the  94  isolates  investigated,  80  (85.1%)  were  multidrug  resistant  (MDR).
The  A.  baumannii  PFGE  clone  A  and  subclone  A1  were  the  most  prevalent  in  patients
infected  with  MDR  isolates.  Fifty-ﬁve  (94.8%)  and  15  (41.7%)  of  the  MDR  isolates
from  the  Adan  and  Mubarak  hospitals,  respectively,  belonged  to  PFGE  clone  A;  iso-
lates  in  this  group  showed  higher  resistance  rates  to  antibiotics  than  isolates  form
other  groups.  Of  the  94  isolates,  40  (42.6%)  were  resistant  to  either  imipenem  or
meropenem  or  to  both  (CRAB).  Most  CRAB  isolates  (29/40  or  72.5%)  carried  bla  genes,
which  code  for  MBL  (VIM-2  and  IMP-1)  enzymes.  Two  isolates  harbored  blaOXA-23.
Conclusion:  Three  distinct  clones  of  CRAB  were  isolated,  providing  evidence  of  a
high  diversity  of  carbapenemases  among  our  geographically  related  isolates.
©  2011  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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Shree  distinct  clones  of  carbapenem-resistant  Acin
ntroduction
nterest  in  Acinetobacter  baumannii  has  grown
apidly  over  the  last  two  decades,  primarily  as  a
esult of  the  emergence  and  outbreak  of  multidrug-
esistant  (MDR)  strains  [1].  A.  baumannii  represents
n important  cause  of  nosocomial  infections  includ-
ng septicemia,  ventilator-associated  pneumonia
nd urinary  tract  infections  [2].  The  bacterium  is
sually intrinsically  resistant  to  multiple  antimi-
robial  agents,  and  resistance  to  -lactam  is  most
ommonly  associated  with  the  production  of  high
evels of  naturally  produced  cephalosporinases
3]. However,  acquired  metallo--lactamase  (MBL)
nzymes,  which  confer  resistance  to  the  carbapen-
ms,  have  been  reported  [4].  Recent  reports  have
hown  that  MBLs,  such  as  PER-1,  VIM-2  and  IMP-1,
re prevalent  in  Turkey  and  Korea  and  are  a growing
ource  of  resistance  in  these  countries  [5,6].  The
issemination  of  the  OXA-23  and  OXA-58  carbapen-
mases  among  A.  baumannii  isolates  has  also  been
eported  in  hospitals  in  Argentina  [7,8].  In  addition,
ospitals  in  the  UK  have  experienced  outbreaks
ith three  widespread  clones:  the  ‘‘South  East’’
lone,  OXA-23  clone  1  and  OXA-23  clone  2;  the  lat-
er two  are  consistently  resistant  to  imipenem  and
eropenem  [9,10].
Recently,  infections  due  to  MDR  A.  baumannii
trains have  become  a  serious  problem  in  some  hos-
itals in  Kuwait,  particularly  the  Mubarak  Al-Kabeer
nd Al-Adan  hospitals,  where  these  isolates  are  the
econd most  frequently  isolated  pathogens,  par-
icularly  in  the  ICUs  [11].  The  Mubarak  Al-Kabeer
ospital is  the  primary  teaching  hospital  and  serves
s both  a  referral  and  secondary  medical  center,
hereas Al-Adan  hospital,  also  a  teaching  hospi-
al, is  a  secondary  medical  center,  located  16  km
way, in  the  southern  part  of  the  country.  This
tudy was  designed  to  investigate  the  clonal  relat-
dness of  the  carbapenem-resistant  A.  baumannii
trains  isolated  from  infected  patients  in  these
ospitals.
aterials and methods
acterial isolates
ll  consecutive  clinically  signiﬁcant  A.  bauman-
ii isolates  collected  from  patients  with  proven
nfections requiring  antimicrobial  therapy  were
ollected  from  the  Mubarak  Al-Kabeer  hospi-
al (MKH,  Kuwait)  and  the  Al-Adan  hospital
ADH, Kuwait)  between  May  and  October  2007.
nly one  isolate  per  patient  was  tested,  and
b
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ll duplicate  strains  were  excluded.  Primary
dentiﬁcation was  performed  using  the  API  20
E system  (BioMerieux,  l’Étoile,  France)  and
onﬁrmed  by  PCR  using  the  following  primers:
′-CTAATAATTGATCTACTCAAG-3′ (blaOXA-69Af) and′-CCAGTGGATGGATGGATAGATTATC-3′ (blaOXA-69r)
or the  blaOXA-69 gene,  a naturally  occurring  oxacil-
inase in  A.  baumannii. Isolates  were  serially
abeled with  abbreviations  reﬂecting  the  hospital
t which  they  were  collected  (1—58  ADH  and  59—94
KH).
usceptibility test
usceptibility  testing  of  the  isolates  was  carried  out
y determining  the  minimum  inhibitory  concentra-
ions  (MICs)  of  11  antibiotics  commonly  used  in  our
ospitals to  treat  gram-negative  infections  using
he Etest  (AB  Biodisk,  Solana,  Sweden).  Brieﬂy,  a
acterial suspension  with  a  turbidity  of  1.0  McFar-
and was  prepared  by  inoculating  a  single  colony
f an  overnight  (16—18  h)  pure  culture  of  the  bac-
erium  into  sterile  PBS.  Using  a sterile  disposable
otton swab  soaked  in  the  inoculum,  a  150  mm
ueller-Hinton  agar  (Becton  Dickinson,  Sparks,  MD,
SA) plate  was  inoculated  in  three  directions  and
pread to  completely  cover  the  entire  surface.
ix Etest  strips  of  the  antibiotics  were  placed  on
ach plate.  The  inoculated  plates  were  then  incu-
ated at  37 ◦C  for  24  h.  An  inoculated  plate  without
ntibiotics was  also  included  in  each  run  to  check
or the  purity  of  the  suspension.  The  MIC  values
ere estimated  based  on  the  concentration  of  the
ntibiotics  at which  the  elliptical  zone  of  inhibition
ntersected  the  Etest  strip.  The  results  were  inter-
reted  according  to  criteria  suggested  by  the  CLSI
12]. Escherichia  coli  ATCC  25922  and  Pseudomonas
eruginosa ATCC  27853  were  included  in  each  run
s controls.
etection of metallo--lactamase (MBL) and
xacillinase (OXA)
trains  showing  non-susceptibility  to  the  car-
apenems  were  screened  for  production  of  MBLs
sing the  disk  approximation  test  as  described  by
ee et  al.  [13]  and  the  MBL  Etest  (AB  Biodisk,
weden). Detection  of  the  blaIMP-1, blaVIM-1,
laVIM-2, blaSPM-1, blaOXA-23, blaOXA-24 and  blaOXA-58
enes  in  carbapenem-resistant  isolates  was  per-
ormed  under  standard  PCR  conditions  using
reviously reported  primers  [14—16].
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Typing by pulsed-ﬁeld gel electrophoresis
(PFGE)
Carbapenem-resistant  isolates  were  typed  by  PFGE
using Apa1  enzyme  according  to  a  method  previ-
ously  published  by  Tenover  et  al.  [17].  Restriction
fragments were  separated  by  electrophoresis  on  a
CHEF DR  II  (Bio-Rad,  California,  USA).  The  gel  was
stained with  1  mg/ml  ethidium  bromide  and  visu-
alized  under  ultraviolet  illumination.  Gel  images
were  analyzed  using  the  Gene  Genius  Imaging  sys-
tem (Syngene  Corp.,  Maryland,  USA).
Results
A  total  of  94  consecutive  isolates,  36  from  MKH
and 58  from  ADH,  were  studied.  The  isolates  were
obtained  from  patients  with  various  types  of  infec-
tions: 35  (37.2%)  had  respiratory  tract  infections,
21 (22.3%)  had  bloodstream  infections,  14  (14.9%)
had wound  infections,  9  (9.6%)  had  urinary  tract
infections  and  15  (16%)  had  miscellaneous  infec-
tions. Comparative  susceptibility  data  between  the
2 hospitals  are  shown  in  Table  1.  All  94  isolates
were multidrug  resistant  (MDR),  which  is  deﬁned
as resistance  to  3  or  more  classes  of  antibiotics;
40 (42.6%)  of  these  isolates  were  resistant  to
the carbapenems  (imipenem  and/or  meropenem).
The MICs  of  imipenem  and  meropenem  ranged
between 0.125  g/ml  and  >32  g/ml,  with  MIC90
values  of  12  g/ml  and  24  g/ml  and  overall
resistance rates  of  19.2%  and  43.6%,  respec-
tively. Among  the  40  carbapenem-nonsusceptible
t
c
i
Table  1  Antimicrobial  susceptibility  pattern  of  A.  bauman
Antimicrobial  agents  Mubarak-Al-Kabeer
hospital
MICs  (g/ml)
MIC50 MIC90 %  res
(n  =  3
Amikacin >256  >256  86  
aAmox-clav  96  >256  97  
Cefepime  >256  >256  77.8
Ceftazidime  >256  >256  77.8
Ciproﬂoxacin  >32  >32  83  
Colistin  0.75  4  16.7
Gentamicin  24  256  77.8
Imipenem  3  12  27.8
Meropenem  4  24  50  
bPip-tazo  >256  >256  77.8
Tigecycline  0.25  2  5.6
a Amoxicillin-clavulanic acid.
b Piperacillin-tazobactam.N.A.  Al-Sweih  et  al.
MIC  ≥8  g/ml)  A.  baumannii  isolates,  only  18
45%) were  imipenem-nonsusceptible,  but  all
ere meropenem-nonsusceptible.  MKH  isolates  dis-
layed higher  resistance  rates  to  imipenem  and
eropenem  (27.8  and  50%,  respectively)  than
hose  from  ADH  (13.8  and  39.7%,  respectively)
Table 2).  Among  the  total  isolates,  7 (7.5%)
ere resistant  to  colistin  and  9  (9.6%)  to  tige-
ycline. The  9  tigecycline-resistant  isolates  were
lso resistant  to  all  other  antibiotics,  including
mipenem and  meropenem.  All  isolates  displayed
esistance rates  to  amikacin,  amoxicillin-clavulanic
cid, cefepime,  ciproﬂoxacin,  gentamicin  and
iperacillin-tazobactam  that  were  above  84%.  The
esistance rates  and  MICs  of  these  antibiotics  were
igniﬁcantly  higher  in  isolates  from  the  Adan  hospi-
al than  the  Mubarak  hospital.
Investigation  of  the  presence  of  several  genes
elated to  carbapenem  resistance  in  all  the  40  A.
aumannii  (CRAB)  isolates  revealed  that,  although
o isolates  harbored  the  blaSPM-1,  blaOXA-24 and
laOXA-58 genes,  blaIMP-1,  blaVIM-2,  blaVIM-1 and
laOXA-23 were  detected  in  29  (72.5%)  isolates.  Of
he 29  isolates  carrying  bla  genes,  8  (34.7%)  har-
ored blaIMP-1 (all  from  ADH),  18  (58.8%)  harbored
he blaVIM-2 gene,  one  strain  from  each  hospital  har-
ored  blaOXA-23, and  one  strain  from  MKH  carried
he blaVIM-1 gene.
Molecular  typing  of  the  29  bla-gene-positive  iso-
ates revealed  three  distinct  PFGE  patterns  (clones
, B  and  C).  Using  PCR,  8  isolates  were  found
o be  positive  for  the  production  of  VIM-2-like
arbapenemases  among  the  ADH  isolates;  these  8
solates belonged  to  subclone  A1,  as  shown  in  the
nii  isolates.
Al-Adan
hospital
MICs  (g/ml)
istance
6)
MIC50 MIC90 %  resistance
(n  =  58)
>256  >256  94.8
>256  >256  100
 >256  >256  91
 >256  >256  93
>32  >32  94.8
 1  1.5  1.7
 48  >1024  91
 2  16  13.8
4  32  39.7
 >256  >256  94.8
 1.5  4  13.8
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Table  2  Carbapenem  resistance  in  relation  to  PFGE  clones  and  presence  of  carbapenemase  enzymes.
Isolate  PFGE  clone  MIC  (g/ml)  MBL  gene  group  OXA  gene  group
Imipenem Meropenem
ADH1 A 16  >32  IMP-1  69
ADH6 A 32 32 IMP-1 69
ADH7  A1  2  32  VIM-2  69
ADH9  A  16  32  IMP-1  69
ADH13  A1  16  32  VIM-2  69
ADH17  A  32  >32  IMP-1  69
ADH18  A  32  >32  IMP-1  69
ADH20  A1  4  32  VIM-2  69
ADH21 A 32  >32  IMP-1  69
ADH23 A  32  >32  IMP-1  69
ADH31  B  >32  >32  —  23,  69a
ADH35  A  16  32  IMP-1  69
ADH37  A1  1  8  VIM-2  69
ADH43  A1  0.5  8  VIM-2  69
ADH47  A1  0.25  8  VIM-2  69
ADH51  A1  1  8  VIM-2  69
ADH56  A1  2  16  VIM-2  69
MKH4  C  4  16  VIM-1  69
MKH5  A1  16  >32  VIM-2  69
MKH8  A1  4  32  VIM-2  69
MKH12  C  16  >32  VIM-2  69
MKH15  A1  4  >32  VIM-2  69
MKH19  A1  16  32  VIM-2  69
MKH20  C  4  16  VIM-2  69
MKH23  A1  8  8  VIM-2  69
MKH27 C  8  32  VIM-2  69
MKH29 B >32  >32  —  23,  69a
MKH30 C  16  32  VIM-2  69
MKH36 C 16  32  VIM-2  69
ADH, Adan hospital; MKH, Mubarak Al Kabir hospital; MBL, metallo--lactamase; OXA, oxacillinase; PFGE, pulsed-ﬁeld gel elec-
trophoresis.
a Oxacillinase-producing carbapenem-resistant A. baumannii (CRAB) isolate from a bloodstream infection in a patient in Adan
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endrogram  (Fig.  1).  The  MICs  of  imipenem
0.25—4 g/ml)  for  7  of  these  8  isolates  were  in  the
usceptible  range,  but  all  isolates  had  meropenem
IC values  ≥8  g/ml.  Isolates  harboring  blaVIM-2
ere  predominant  among  the  MKH  strains  and
elonged  to  either  subclone  A1  (5  isolates)  or  clone
 (5  isolates).  Only  3  (30%)  of  these  displayed  an
mipenem  MIC  of  4  g/ml,  but  all  were  consistently
esistant to  meropenem  (MICs  16  to  >32  g/ml).
All 8  isolates  harboring  blaIMP-1 were  from  ADH
nd belonged  to  clone  A;  no  clone  A  isolate  was
bserved  at  MKH.  One  isolate  in  each  hospital  was
ositive  for  blaOXA-23 and  belonged  to  clone  B.
hese two  isolates,  together  with  those  of  clone  A
arboring bla ,  were  unequivocally  resistant  toIMP-1
mipenem  and  meropenem  (MICs  16  to  >32  g/ml).
 single  isolate  positive  for  blaVIM-1 was  from  a
atient in  MKH  and  belonged  to  clone  C.
d
r
a
pital assigned into PFGE clone B.
iscussion
lthough  similar  to  world  trends,  the  results  of
his study  demonstrate  an  unacceptably  high  rate
f resistance  to  carbapenems  in  A.  baumannii
solates collected  from  hospitalized  patients  in
uwait. There  is  worldwide  variation  in  the  car-
apenem  resistance  rate  from  one  geographical
rea to  another,  but  a  recent  report  by  Perez  et  al.
1] conﬁrmed  an  increasing  worldwide  incidence
f carbapenem-resistant  A.  baumannii  (CRAB).  For
nstance, the  global  incidence  of  meropenem  resis-
ance in  A.  baumannii  was  approximately  6%  in
998 but  jumped  to  approximately  29%  in  2005.  This
evelopment  also  applies  to  our  hospitals,  where
esistance  rates  to  imipenem  and  meropenem  were
s high  as  28%  and  50%,  respectively,  in  one  hos-
ital and  14%  and  40%,  respectively,  in  the  other.
106  N.A.  Al-Sweih  et  al.
Figure  1  Genetic  relationships  of  29  carbapenem-resistant  Acinetobacter  baumannii  isolates  harboring  MBL  and  Oxa
bla  genes  constructed  from  cluster  analysis  of  PFGE  patterns  obtained  after  restriction  treatment  with  Apa  I. Hospital
strains  (MKH,  Mubarak  Al  Kabir  Hospital;  ADH,  Adan  Hospital),  clones  (A,  A1,  B,  C),  bla  genes  (VIM-1,  VIM-2,  IMP-1;
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Thus,  the  choice  of  antimicrobial  agents  available
for treating  A.  baumannii  infections  is  limited.
The high  carbapenem  resistance  rates  in  strains
from our  hospitals  are  concordant  with  a  recent
report from  nearby  Turkey,  where  50%  of  their  iso-
lates displayed  resistance  to  carbapenems  [18].
In this  study,  CRAB  isolates  also  demonstrated
high rates  of  co-resistance  to  all  other  classes  of
antimicrobial  agents  tested,  except  tigecycline  and
colistin. Isolates  from  both  hospitals  showed  an
unpredictable  susceptibility  pattern  to  the  latter
drugs. In  MKH,  all  carbapenem-susceptible  isolates
were susceptible  to  tigecycline  but  less  susceptible
to colistin,  whereas  approximately  12%  of  the  CRAB
isolates  that  were  resistant  to  tigecycline  were
relatively  susceptible  to  colistin.  As  the  testing
media  for  both  sets  of  isolates  were  the  same,  the
explanation  for  this  observation  remains  unclear.
i
a
t
h.  baumannii  isolates  with  high-level  resistance
ates against  tigecycline  have  recently  emerged
s a  potential  problem  of clinical  signiﬁcance  in
ifferent  parts  of  the  world  [19,20].  Relative  to  pre-
iously reported  rates  of  1.1%  and  0%  from  Kuwait
21], the  prevalence  of  tigecycline  resistance  has
ncreased  phenomenally  (in  just  over  two  years)
bserved  in  this  study  cannot  be  explained.  The
ethods  of  testing,  including  media,  used  in  both
he previous  study  and  our  study  were  precisely  the
ame. We  report  that  17%  of  the  MKH  isolates  were
esistant  to  colistin.  This  ﬁnding  is  of  great  concern
ecause  the  spread  of  these  resistant  strains  will
ompromise  the  treatment  of  MDR  Acinetobacter
nfections, especially  as  colistin  is  one  of  the  last
lternatives  to  carbapenems.  One  possible  explana-
ion may  be  the  presence  of  a  pmrA  mutation  that
as been  shown  to  be  related  to  elevated  colistin
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of Hospital Infection 2004;58:170—9.
[10] Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner
M, Pike R, et al. Detection and typing of integronshree  distinct  clones  of  carbapenem-resistant  Acin
esistance  in  A.  baumannii  [22].  However,  the  col-
stin resistance  mechanisms  should  be  investigated
n greater  detail.
The  acquisition  of  carbapenem  resistance  in
. baumannii  is  mainly  due  to  the  production  of
wo types  of  -lactamases:  OXA-type  -lactamases
OBLs) and  metallo--lactamases  (MBLs).  The  OBLs
ppear to  be  more  prevalent  and  important  to
arbapenem  resistance  in  this  bacterium  in  some
ountries  [2—4,23],  including  Middle  Eastern  coun-
ries such  as  Bahrain  [24]  and  the  UAE  [25].
owever,  the  blaVIM-2 and  blaIMP-1 genes  were
esponsible  for  the  majority  of  carbapenem  resis-
ance in  our  isolates.  Only  two  strains  (one  from
ach  hospital)  harboring  the  blaOXA-23 gene  were
solated. The  blaIMP-1 and  blaVIM-2 genes  have  been
eported with  increased  frequency  as  mediators  of
arbapenem  resistance  in  Acinetobacter  isolates
rom Asia  and  Europe  [26,27]  and,  more  recently,
rom  Canada  and  South  America  [28,29].  No  previ-
us data  are  available  about  these  genes  in  isolates
btained  from  the  GCC  or  Middle  East.  Thus,  our
tudy constitutes  the  ﬁrst  report  from  this  part
f the  world  on  CRAB  isolates  whose  carbapenem-
esistance is  mediated  mainly  by  MBLs.  A  sizable
ercentage  of  CRAB  isolates  (27.5%)  were  nega-
ive for  all  of  the  MBL  and  OXA  genes  investigated.
ence, we  can  speculate  that  the  resistance  in
hese isolates  may  be  due  to  non-enzymatic  mech-
nisms  such  as  efﬂux  pump  and  porin  defects.
lternatively,  resistance  could  be  due  to  the
roduction of  the  NDM-1  -lactamase  or  its  vari-
nt,  NDM-2,  which  has  been  found  in  a  clinical
solate in  Egypt  [30].  The  Egyptian  diaspora  is
he largest  expatriate  population  in  Kuwait,  and
trains showing  the  latter  mechanism  of  resistance
ay have  been  introduced  into  the  population
y returning  workers  and  should  be  meticulously
nvestigated.
The analysis  of  the  clonal  patterns  obtained  by
FGE for  the  29  carbapenem-resistant  Acinetobac-
er isolates,  which  were  positive  for  at  least  one
f the  tested  MBL  and  oxacillinase  genes,  showed
hat  the  CRAB  isolates  belonged  to  3  major  clones.
he most  common  clones  in  MKH  were  C  and  A.  All
solates from  ADH  belonged  to  clone  A,  except  for  a
ingle isolate  that  belonged  to  clone  B.  These  ﬁnd-
ngs reﬂect  the  spread  and  dissemination  of  clone
 and  subclone  A1  between  the  hospitals,  but  no
vidence  of  inter-hospital  dissemination  of  clones  B
nd C  was  observed.  These  results  indicate  that  lim-
ted clones  of  A.  baumannii  may  have  the  capacity
o acquire  carbapenem  resistance.  It  is  conceivable
hat the  acquisition  of  carbapenem  resistance  may
ontribute  to  the  survival  of  A.  baumannii  in  the
ospital  environment.acter  baumannii  107
onclusion
he  identiﬁcation  of  resistance  genes  conﬁrms  the
igh diversity  of  different  carbapenemases  in  geo-
raphically  related  A.  baumannii  isolates.  Thus,  the
igh prevalence  of  MDR  and  carbapenem-resistant
solates  in  these  hospitals  may  be  due  to  more
han one  clone  of  A.  baumannii.  This  ﬁnding  is
nusual,  deserves  more  attention,  and  warrants
urther  investigation  of  the  population-genetics
ackground  of  the  isolates.
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